English
简体中文
Total: £ 56.28
Published Date: 2026-02-12 | Pages: 116 | Tables: 120 | Medical Care
The global Rubella Recombinant Antigen market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Rubella Recombinant Antigen is a protein produced by genetic engineering technology that mimics the natural antigen of the rubella virus. Rubella virus is the virus that causes rubella, a common infectious disease that is particularly dangerous in pregnant women because infection may lead to congenital rubella syndrome in the fetus. Recombinant antigens are used in in vitro diagnostic reagents to detect immune responses caused by rubella infection (such as the presence of antibodies), and are used in vaccine development and basic research.
The North American market for Rubella Recombinant Antigen is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Rubella Recombinant Antigen is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Rubella Recombinant Antigen in In Vitro Diagnostics is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Rubella Recombinant Antigen include Creative Biomart, RayBiotech, ProSpec, Abcam, Bio-Rad Laboratories, Fapon Biotech, QED Bioscience, Cusabio, Meridian Bioscience, Native Antigen Company, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Rubella Recombinant Antigen market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Rubella Recombinant Antigen. The Rubella Recombinant Antigen market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Rubella Recombinant Antigen market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Rubella Recombinant Antigen manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Creative Biomart
RayBiotech
ProSpec
Abcam
Bio-Rad Laboratories
Fapon Biotech
QED Bioscience
Cusabio
Meridian Bioscience
Native Antigen Company
SERION Immunologics
ViroGen Corporation
Segment by Type
Rubella Protein Purity >90%
Rubella Protein Purity >95%
Rubella Protein Purity >98%
Others
Segment by Application
In Vitro Diagnostics
Vaccine Development
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Rubella Recombinant Antigen companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Rubella Recombinant Antigen Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Rubella Protein Purity >90%
1.2.3 Rubella Protein Purity >95%
1.2.4 Rubella Protein Purity >98%
1.2.5 Others
1.3 Market by Application
1.3.1 Global Rubella Recombinant Antigen Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 In Vitro Diagnostics
1.3.3 Vaccine Development
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rubella Recombinant Antigen Market Perspective (2021–2032)
2.2 Global Rubella Recombinant Antigen Growth Trends by Region
2.2.1 Global Rubella Recombinant Antigen Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Rubella Recombinant Antigen Historic Market Size by Region (2021–2026)
2.2.3 Rubella Recombinant Antigen Forecasted Market Size by Region (2027–2032)
2.3 Rubella Recombinant Antigen Market Dynamics
2.3.1 Rubella Recombinant Antigen Industry Trends
2.3.2 Rubella Recombinant Antigen Market Drivers
2.3.3 Rubella Recombinant Antigen Market Challenges
2.3.4 Rubella Recombinant Antigen Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rubella Recombinant Antigen Players by Revenue
3.1.1 Global Top Rubella Recombinant Antigen Players by Revenue (2021–2026)
3.1.2 Global Rubella Recombinant Antigen Revenue Market Share by Players (2021–2026)
3.2 Global Top Rubella Recombinant Antigen Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Rubella Recombinant Antigen Revenue
3.4 Global Rubella Recombinant Antigen Market Concentration Ratio
3.4.1 Global Rubella Recombinant Antigen Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rubella Recombinant Antigen Revenue in 2025
3.5 Global Key Players of Rubella Recombinant Antigen Head Offices and Areas Served
3.6 Global Key Players of Rubella Recombinant Antigen, Products and Applications
3.7 Global Key Players of Rubella Recombinant Antigen, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Rubella Recombinant Antigen Breakdown Data by Type
4.1 Global Rubella Recombinant Antigen Historic Market Size by Type (2021–2026)
4.2 Global Rubella Recombinant Antigen Forecasted Market Size by Type (2027–2032)
5 Rubella Recombinant Antigen Breakdown Data by Application
5.1 Global Rubella Recombinant Antigen Historic Market Size by Application (2021–2026)
5.2 Global Rubella Recombinant Antigen Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Rubella Recombinant Antigen Market Size (2021–2032)
6.2 North America Rubella Recombinant Antigen Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Rubella Recombinant Antigen Market Size by Country (2021–2026)
6.4 North America Rubella Recombinant Antigen Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rubella Recombinant Antigen Market Size (2021–2032)
7.2 Europe Rubella Recombinant Antigen Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Rubella Recombinant Antigen Market Size by Country (2021–2026)
7.4 Europe Rubella Recombinant Antigen Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Rubella Recombinant Antigen Market Size (2021–2032)
8.2 Asia-Pacific Rubella Recombinant Antigen Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Rubella Recombinant Antigen Market Size by Region (2021–2026)
8.4 Asia-Pacific Rubella Recombinant Antigen Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Rubella Recombinant Antigen Market Size (2021–2032)
9.2 Latin America Rubella Recombinant Antigen Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Rubella Recombinant Antigen Market Size by Country (2021–2026)
9.4 Latin America Rubella Recombinant Antigen Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rubella Recombinant Antigen Market Size (2021–2032)
10.2 Middle East & Africa Rubella Recombinant Antigen Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Rubella Recombinant Antigen Market Size by Country (2021–2026)
10.4 Middle East & Africa Rubella Recombinant Antigen Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Creative Biomart
11.1.1 Creative Biomart Company Details
11.1.2 Creative Biomart Business Overview
11.1.3 Creative Biomart Rubella Recombinant Antigen Introduction
11.1.4 Creative Biomart Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.1.5 Creative Biomart Recent Development
11.2 RayBiotech
11.2.1 RayBiotech Company Details
11.2.2 RayBiotech Business Overview
11.2.3 RayBiotech Rubella Recombinant Antigen Introduction
11.2.4 RayBiotech Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.2.5 RayBiotech Recent Development
11.3 ProSpec
11.3.1 ProSpec Company Details
11.3.2 ProSpec Business Overview
11.3.3 ProSpec Rubella Recombinant Antigen Introduction
11.3.4 ProSpec Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.3.5 ProSpec Recent Development
11.4 Abcam
11.4.1 Abcam Company Details
11.4.2 Abcam Business Overview
11.4.3 Abcam Rubella Recombinant Antigen Introduction
11.4.4 Abcam Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.4.5 Abcam Recent Development
11.5 Bio-Rad Laboratories
11.5.1 Bio-Rad Laboratories Company Details
11.5.2 Bio-Rad Laboratories Business Overview
11.5.3 Bio-Rad Laboratories Rubella Recombinant Antigen Introduction
11.5.4 Bio-Rad Laboratories Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.5.5 Bio-Rad Laboratories Recent Development
11.6 Fapon Biotech
11.6.1 Fapon Biotech Company Details
11.6.2 Fapon Biotech Business Overview
11.6.3 Fapon Biotech Rubella Recombinant Antigen Introduction
11.6.4 Fapon Biotech Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.6.5 Fapon Biotech Recent Development
11.7 QED Bioscience
11.7.1 QED Bioscience Company Details
11.7.2 QED Bioscience Business Overview
11.7.3 QED Bioscience Rubella Recombinant Antigen Introduction
11.7.4 QED Bioscience Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.7.5 QED Bioscience Recent Development
11.8 Cusabio
11.8.1 Cusabio Company Details
11.8.2 Cusabio Business Overview
11.8.3 Cusabio Rubella Recombinant Antigen Introduction
11.8.4 Cusabio Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.8.5 Cusabio Recent Development
11.9 Meridian Bioscience
11.9.1 Meridian Bioscience Company Details
11.9.2 Meridian Bioscience Business Overview
11.9.3 Meridian Bioscience Rubella Recombinant Antigen Introduction
11.9.4 Meridian Bioscience Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.9.5 Meridian Bioscience Recent Development
11.10 Native Antigen Company
11.10.1 Native Antigen Company Company Details
11.10.2 Native Antigen Company Business Overview
11.10.3 Native Antigen Company Rubella Recombinant Antigen Introduction
11.10.4 Native Antigen Company Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.10.5 Native Antigen Company Recent Development
11.11 SERION Immunologics
11.11.1 SERION Immunologics Company Details
11.11.2 SERION Immunologics Business Overview
11.11.3 SERION Immunologics Rubella Recombinant Antigen Introduction
11.11.4 SERION Immunologics Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.11.5 SERION Immunologics Recent Development
11.12 ViroGen Corporation
11.12.1 ViroGen Corporation Company Details
11.12.2 ViroGen Corporation Business Overview
11.12.3 ViroGen Corporation Rubella Recombinant Antigen Introduction
11.12.4 ViroGen Corporation Revenue in Rubella Recombinant Antigen Business (2021–2026)
11.12.5 ViroGen Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Rubella Recombinant Antigen Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Rubella Protein Purity >90%
Table 3. Key Players of Rubella Protein Purity >95%
Table 4. Key Players of Rubella Protein Purity >98%
Table 5. Key Players of Others
Table 6. Global Rubella Recombinant Antigen Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Rubella Recombinant Antigen Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Rubella Recombinant Antigen Market Size by Region (US$ Million), 2021–2026
Table 9. Global Rubella Recombinant Antigen Market Share by Region (2021–2026)
Table 10. Global Rubella Recombinant Antigen Forecasted Market Size by Region (US$ Million), 2027–2032
Table 11. Global Rubella Recombinant Antigen Market Share by Region (2027–2032)
Table 12. Rubella Recombinant Antigen Market Trends
Table 13. Rubella Recombinant Antigen Market Drivers
Table 14. Rubella Recombinant Antigen Market Challenges
Table 15. Rubella Recombinant Antigen Market Restraints
Table 16. Global Rubella Recombinant Antigen Revenue by Players (US$ Million), 2021–2026
Table 17. Global Rubella Recombinant Antigen Market Share by Players (2021–2026)
Table 18. Global Top Rubella Recombinant Antigen Players by Tier (Tier 1, Tier 2, and Tier 3), based on Rubella Recombinant Antigen Revenue, 2025
Table 19. Ranking of Global Top Rubella Recombinant Antigen Companies by Revenue (US$ Million) in 2025
Table 20. Global 5 Largest Players Market Share by Rubella Recombinant Antigen Revenue (CR5 and HHI), 2021–2026
Table 21. Global Key Players of Rubella Recombinant Antigen, Headquarters and Area Served
Table 22. Global Key Players of Rubella Recombinant Antigen, Products and Applications
Table 23. Global Key Players of Rubella Recombinant Antigen, Date of General Availability (GA)
Table 24. Mergers and Acquisitions, Expansion Plans
Table 25. Global Rubella Recombinant Antigen Market Size by Type (US$ Million), 2021–2026
Table 26. Global Rubella Recombinant Antigen Revenue Market Share by Type (2021–2026)
Table 27. Global Rubella Recombinant Antigen Forecasted Market Size by Type (US$ Million), 2027–2032
Table 28. Global Rubella Recombinant Antigen Revenue Market Share by Type (2027–2032)
Table 29. Global Rubella Recombinant Antigen Market Size by Application (US$ Million), 2021–2026
Table 30. Global Rubella Recombinant Antigen Revenue Market Share by Application (2021–2026)
Table 31. Global Rubella Recombinant Antigen Forecasted Market Size by Application (US$ Million), 2027–2032
Table 32. Global Rubella Recombinant Antigen Revenue Market Share by Application (2027–2032)
Table 33. North America Rubella Recombinant Antigen Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 34. North America Rubella Recombinant Antigen Market Size by Country (US$ Million), 2021–2026
Table 35. North America Rubella Recombinant Antigen Market Size by Country (US$ Million), 2027–2032
Table 36. Europe Rubella Recombinant Antigen Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. Europe Rubella Recombinant Antigen Market Size by Country (US$ Million), 2021–2026
Table 38. Europe Rubella Recombinant Antigen Market Size by Country (US$ Million), 2027–2032
Table 39. Asia-Pacific Rubella Recombinant Antigen Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 40. Asia-Pacific Rubella Recombinant Antigen Market Size by Region (US$ Million), 2021–2026
Table 41. Asia-Pacific Rubella Recombinant Antigen Market Size by Region (US$ Million), 2027–2032
Table 42. Latin America Rubella Recombinant Antigen Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Latin America Rubella Recombinant Antigen Market Size by Country (US$ Million), 2021–2026
Table 44. Latin America Rubella Recombinant Antigen Market Size by Country (US$ Million), 2027–2032
Table 45. Middle East & Africa Rubella Recombinant Antigen Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Middle East & Africa Rubella Recombinant Antigen Market Size by Country (US$ Million), 2021–2026
Table 47. Middle East & Africa Rubella Recombinant Antigen Market Size by Country (US$ Million), 2027–2032
Table 48. Creative Biomart Company Details
Table 49. Creative Biomart Business Overview
Table 50. Creative Biomart Rubella Recombinant Antigen Product
Table 51. Creative Biomart Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 52. Creative Biomart Recent Development
Table 53. RayBiotech Company Details
Table 54. RayBiotech Business Overview
Table 55. RayBiotech Rubella Recombinant Antigen Product
Table 56. RayBiotech Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 57. RayBiotech Recent Development
Table 58. ProSpec Company Details
Table 59. ProSpec Business Overview
Table 60. ProSpec Rubella Recombinant Antigen Product
Table 61. ProSpec Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 62. ProSpec Recent Development
Table 63. Abcam Company Details
Table 64. Abcam Business Overview
Table 65. Abcam Rubella Recombinant Antigen Product
Table 66. Abcam Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 67. Abcam Recent Development
Table 68. Bio-Rad Laboratories Company Details
Table 69. Bio-Rad Laboratories Business Overview
Table 70. Bio-Rad Laboratories Rubella Recombinant Antigen Product
Table 71. Bio-Rad Laboratories Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 72. Bio-Rad Laboratories Recent Development
Table 73. Fapon Biotech Company Details
Table 74. Fapon Biotech Business Overview
Table 75. Fapon Biotech Rubella Recombinant Antigen Product
Table 76. Fapon Biotech Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 77. Fapon Biotech Recent Development
Table 78. QED Bioscience Company Details
Table 79. QED Bioscience Business Overview
Table 80. QED Bioscience Rubella Recombinant Antigen Product
Table 81. QED Bioscience Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 82. QED Bioscience Recent Development
Table 83. Cusabio Company Details
Table 84. Cusabio Business Overview
Table 85. Cusabio Rubella Recombinant Antigen Product
Table 86. Cusabio Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 87. Cusabio Recent Development
Table 88. Meridian Bioscience Company Details
Table 89. Meridian Bioscience Business Overview
Table 90. Meridian Bioscience Rubella Recombinant Antigen Product
Table 91. Meridian Bioscience Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 92. Meridian Bioscience Recent Development
Table 93. Native Antigen Company Company Details
Table 94. Native Antigen Company Business Overview
Table 95. Native Antigen Company Rubella Recombinant Antigen Product
Table 96. Native Antigen Company Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 97. Native Antigen Company Recent Development
Table 98. SERION Immunologics Company Details
Table 99. SERION Immunologics Business Overview
Table 100. SERION Immunologics Rubella Recombinant Antigen Product
Table 101. SERION Immunologics Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 102. SERION Immunologics Recent Development
Table 103. ViroGen Corporation Company Details
Table 104. ViroGen Corporation Business Overview
Table 105. ViroGen Corporation Rubella Recombinant Antigen Product
Table 106. ViroGen Corporation Revenue in Rubella Recombinant Antigen Business (US$ Million), 2021–2026
Table 107. ViroGen Corporation Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Rubella Recombinant Antigen Picture
Figure 2. Global Rubella Recombinant Antigen Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Rubella Recombinant Antigen Market Share by Type: 2025 vs 2032
Figure 4. Rubella Protein Purity >90% Features
Figure 5. Rubella Protein Purity >95% Features
Figure 6. Rubella Protein Purity >98% Features
Figure 7. Others Features
Figure 8. Global Rubella Recombinant Antigen Market Size by Application (US$ Million), 2021–2032
Figure 9. Global Rubella Recombinant Antigen Market Share by Application: 2025 vs 2032
Figure 10. In Vitro Diagnostics Case Studies
Figure 11. Vaccine Development Case Studies
Figure 12. Others Case Studies
Figure 13. Rubella Recombinant Antigen Report Years Considered
Figure 14. Global Rubella Recombinant Antigen Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 15. Global Rubella Recombinant Antigen Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Rubella Recombinant Antigen Market Share by Region: 2025 vs 2032
Figure 17. Global Rubella Recombinant Antigen Market Share by Players in 2025
Figure 18. Global Rubella Recombinant Antigen Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Rubella Recombinant Antigen Revenue in 2025
Figure 20. North America Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. North America Rubella Recombinant Antigen Market Share by Country (2021–2032)
Figure 22. United States Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Canada Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Rubella Recombinant Antigen Market Share by Country (2021–2032)
Figure 26. Germany Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. France Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. U.K. Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Italy Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Russia Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Ireland Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Rubella Recombinant Antigen Market Share by Region (2021–2032)
Figure 34. China Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Japan Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. South Korea Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Southeast Asia Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. India Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Australia & New Zealand Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Rubella Recombinant Antigen Market Share by Country (2021–2032)
Figure 42. Mexico Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Brazil Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Rubella Recombinant Antigen Market Share by Country (2021–2032)
Figure 46. Israel Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Saudi Arabia Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. UAE Rubella Recombinant Antigen Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Creative Biomart Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 50. RayBiotech Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 51. ProSpec Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 52. Abcam Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 53. Bio-Rad Laboratories Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 54. Fapon Biotech Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 55. QED Bioscience Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 56. Cusabio Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 57. Meridian Bioscience Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 58. Native Antigen Company Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 59. SERION Immunologics Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 60. ViroGen Corporation Revenue Growth Rate in Rubella Recombinant Antigen Business (2021–2026)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
